Trial Outcomes & Findings for Allofit® IT With HXPE in Total Hip Arthroplasty (NCT NCT03672929)
NCT ID: NCT03672929
Last Updated: 2026-01-27
Results Overview
The objective of this study is implant survival at 10 years which is assessed by revision of the the study device. Survivorship at 10 years was defined as cases that had the implant still in place at 10 years.
COMPLETED
197 participants
10 years post-surgery
2026-01-27
Participant Flow
Enrollment for this study was initiated in 2011 and was completed in 2017. Medizinische Universitat Wien, Universitatsklinik fur Orthopadie, Austria enrolled 41 patients, CHU de Nantes - Site Nord, France enrolled 36 patients, Kliniken Dr. Erler GmbH, Germany enrolled 50 patients, Orthopadie El Masry, Germany enrolled 40 patients and HUA Santiago enrolled 30 patients
Enrollment for this study was initiated in 2011 and was completed in 2017 with 197 patients enrolled in five participating study centers. One site which enrolled 30 patients is inactive since a long time an only has data up to 1-year Post-OP.
Unit of analysis: implants
Participant milestones
| Measure |
Patients Who Received the Allofit IT With HXPE
Subjects in need of a primary total hip arthroplasty, who met the inclusion/exclusion criteria and who received the Allofit IT Shell in combination with the Longevity HXPE Liners
|
|---|---|
|
Overall Study
STARTED
|
197 197
|
|
Overall Study
COMPLETED
|
98 98
|
|
Overall Study
NOT COMPLETED
|
99 99
|
Reasons for withdrawal
| Measure |
Patients Who Received the Allofit IT With HXPE
Subjects in need of a primary total hip arthroplasty, who met the inclusion/exclusion criteria and who received the Allofit IT Shell in combination with the Longevity HXPE Liners
|
|---|---|
|
Overall Study
Death
|
13
|
|
Overall Study
Lost to Follow-up
|
32
|
|
Overall Study
Withdrawal by Subject
|
18
|
|
Overall Study
Adverse Event
|
3
|
|
Overall Study
Surgery with the device never took place
|
3
|
|
Overall Study
Inactive site
|
30
|
Baseline Characteristics
The gender for 2 participants is not available
Baseline characteristics by cohort
| Measure |
Patients Who Received the Allofit IT With HXPE
n=197 Participants
Subjects in need of a primary total hip arthroplasty, who met the inclusion/exclusion criteria and who received the Allofit IT Shell in combination with the Longevity HXPE Liners
|
|---|---|
|
Age, Continuous
|
63.4 years
STANDARD_DEVIATION 9.2 • n=197 Participants
|
|
Sex: Female, Male
Female
|
104 Participants
n=195 Participants • The gender for 2 participants is not available
|
|
Sex: Female, Male
Male
|
91 Participants
n=195 Participants • The gender for 2 participants is not available
|
|
Region of Enrollment
Austria
|
41 participants
n=197 Participants
|
|
Region of Enrollment
France
|
36 participants
n=197 Participants
|
|
Region of Enrollment
Germany
|
90 participants
n=197 Participants
|
|
Region of Enrollment
Spain
|
30 participants
n=197 Participants
|
|
BMI
|
28.0 kg/m²
STANDARD_DEVIATION 4.7 • n=196 Participants • 1 patient does not have information on weight
|
PRIMARY outcome
Timeframe: 10 years post-surgeryPopulation: All study patients
The objective of this study is implant survival at 10 years which is assessed by revision of the the study device. Survivorship at 10 years was defined as cases that had the implant still in place at 10 years.
Outcome measures
| Measure |
Patients Who Received the Allofit IT With HXPE
n=197 Participants
Subjects in need of a primary total hip arthroplasty, who met the inclusion/exclusion criteria and who received the Allofit IT Shell in combination with the Longevity HXPE Liners
|
|---|---|
|
Survival of the Implant System
|
89 participants
|
SECONDARY outcome
Timeframe: 10 years post-surgeryPopulation: 33 complications involved the study hip
Safety of the system will be assessed by monitoring the frequency and incidence of adverse events.
Outcome measures
| Measure |
Patients Who Received the Allofit IT With HXPE
n=197 Participants
Subjects in need of a primary total hip arthroplasty, who met the inclusion/exclusion criteria and who received the Allofit IT Shell in combination with the Longevity HXPE Liners
|
|---|---|
|
Safety of the Implant System
|
33 complications
|
SECONDARY outcome
Timeframe: pre-op, 6 Months, 1 Year, 2 Year, 3 Year, 5 Year, 7 Year, 10 YearPopulation: Due to lost to follow-up, withdrawals, visit not being performed the number of participants analyzed in each time-point is different
The Harris Hip Score (HHS) is an outcome measure that includes a series of questions answered by the patient and physical examinations recorded by a qualified health care professional. The HHS covers four domains: pain (one item, 0-44 points), function and functional activities (seven items, 0-47 points), absence of deformity (one item, 0-4 points) and range of motion (one item, 0-5 points). To obtain a final score, the points are summed. The outcome score can be categorized as Excellent: 90-100; Good: 80-90; Fair: 70-80; Poor: \< 70
Outcome measures
| Measure |
Patients Who Received the Allofit IT With HXPE
n=185 Participants
Subjects in need of a primary total hip arthroplasty, who met the inclusion/exclusion criteria and who received the Allofit IT Shell in combination with the Longevity HXPE Liners
|
|---|---|
|
Harris Hip Score (HHS)
Pre-Op
|
51.5 score on a scale
Standard Deviation 16.5
|
|
Harris Hip Score (HHS)
6 months
|
92.3 score on a scale
Standard Deviation 10.0
|
|
Harris Hip Score (HHS)
1 Year
|
94.4 score on a scale
Standard Deviation 10.2
|
|
Harris Hip Score (HHS)
2 Year
|
97.1 score on a scale
Standard Deviation 6.0
|
|
Harris Hip Score (HHS)
3 Year
|
96.6 score on a scale
Standard Deviation 6.9
|
|
Harris Hip Score (HHS)
5 Year
|
96.3 score on a scale
Standard Deviation 8.1
|
|
Harris Hip Score (HHS)
7 Year
|
93.0 score on a scale
Standard Deviation 12.6
|
|
Harris Hip Score (HHS)
10 Year
|
96.3 score on a scale
Standard Deviation 7.8
|
SECONDARY outcome
Timeframe: pre-op, 6 Months, 1 Year, 2 Year, 3 Year, 5 Year, 7 Year, 10 YearPopulation: Due to lost to follow-up, withdrawals, visit not being performed the number of participants analyzed in each time-point is different
The EQ-5D-3L is a standardized instrument widely used to measure health status. It is a self-reported assessment about the patient's quality of life composed of two parts: a questionnaire and a visual analogue scale (VAS). The questionnaire includes five dimensions referring to mobility, self-care, daily activities,pain/discomfort, and anxiety/depression. Each question can be answered in three ways/levels indicating no problems, some problems, and extreme problems. In the derived EQ-5D-3L score, the highest score is 1 and the lowest score is -0.594;negative numbers correspond to a self-assessed health state worse than being dead. Higher scores mean a better outcome.
Outcome measures
| Measure |
Patients Who Received the Allofit IT With HXPE
n=193 Participants
Subjects in need of a primary total hip arthroplasty, who met the inclusion/exclusion criteria and who received the Allofit IT Shell in combination with the Longevity HXPE Liners
|
|---|---|
|
EQ-5D-3L Score
Pre-Op
|
0.4 score on a scale
Standard Deviation 0.3
|
|
EQ-5D-3L Score
6 months
|
0.9 score on a scale
Standard Deviation 0.2
|
|
EQ-5D-3L Score
1 Year
|
0.9 score on a scale
Standard Deviation 0.2
|
|
EQ-5D-3L Score
2 Year
|
0.9 score on a scale
Standard Deviation 0.2
|
|
EQ-5D-3L Score
3 Year
|
0.9 score on a scale
Standard Deviation 0.2
|
|
EQ-5D-3L Score
5 Year
|
0.9 score on a scale
Standard Deviation 0.2
|
|
EQ-5D-3L Score
7 Year
|
0.9 score on a scale
Standard Deviation 0.2
|
|
EQ-5D-3L Score
10 Year
|
0.9 score on a scale
Standard Deviation 0.2
|
SECONDARY outcome
Timeframe: pre-op, 6 Months, 1 Year, 2 Year, 3 Year, 5 Year, 7 Year, 10 YearPopulation: Due to lost to follow-up, withdrawals, visit not being performed the number of participants analyzed in each time-point is different
The EQ-5D-3L is a standardized instrument widely used to measure health status. It is a self-reported assessment about the patient's quality of life composed of two parts: a questionnaire and a visual analogue scale (VAS). The VAS is a vertical scale ranging from 100 ('The best health you can imagine') to 0 ('The worst health you can imagine') where the patient reports his/her current state of health. Higher scores mean a better outcome.
Outcome measures
| Measure |
Patients Who Received the Allofit IT With HXPE
n=194 Participants
Subjects in need of a primary total hip arthroplasty, who met the inclusion/exclusion criteria and who received the Allofit IT Shell in combination with the Longevity HXPE Liners
|
|---|---|
|
EQ-5D VAS
Pre-Op
|
52.7 score on a scale
Standard Deviation 21.2
|
|
EQ-5D VAS
6 months
|
73.1 score on a scale
Standard Deviation 19.7
|
|
EQ-5D VAS
1 Year
|
78.4 score on a scale
Standard Deviation 16.6
|
|
EQ-5D VAS
2 Year
|
82.3 score on a scale
Standard Deviation 13.6
|
|
EQ-5D VAS
3 Year
|
82.1 score on a scale
Standard Deviation 14.1
|
|
EQ-5D VAS
5 Year
|
83.2 score on a scale
Standard Deviation 16.3
|
|
EQ-5D VAS
7 Year
|
81.9 score on a scale
Standard Deviation 14.5
|
|
EQ-5D VAS
10 Year
|
78.6 score on a scale
Standard Deviation 16.8
|
SECONDARY outcome
Timeframe: pre-op, 6 Months, 1 Year, 2 Year, 3 Year, 5 Year, 7 Year, 10 YearPopulation: Due to lost to follow-up, withdrawals, visit not being performed the number of participants analyzed in each time-point is different.
The Oxford Hip Score (OHS) is a patient-reported outcome measure that was developed to specifically assess the patient's perspective of outcome following THA. The OHS consists of twelve questions covering function and pain associated with the hip. To calculate the total score, each response is scored from 0 (worst outcome) to 4 (best outcome) and the sum of all 12 items is reported with a maximum of 48, representing the best score possible. The outcome score can be categorized as Excellent: \> 41; Good: 34 - 41; Fair: 27 - 33; Poor: \< 27. Higher scores mean a better outcome.
Outcome measures
| Measure |
Patients Who Received the Allofit IT With HXPE
n=194 Participants
Subjects in need of a primary total hip arthroplasty, who met the inclusion/exclusion criteria and who received the Allofit IT Shell in combination with the Longevity HXPE Liners
|
|---|---|
|
Oxford Hip Score
Pre-Op
|
21.4 score on a scale
Standard Deviation 7.4
|
|
Oxford Hip Score
6 months
|
41.1 score on a scale
Standard Deviation 7.4
|
|
Oxford Hip Score
1 Year
|
43.2 score on a scale
Standard Deviation 6.4
|
|
Oxford Hip Score
2 Year
|
44.8 score on a scale
Standard Deviation 6.1
|
|
Oxford Hip Score
3 Year
|
45.1 score on a scale
Standard Deviation 5.4
|
|
Oxford Hip Score
5 Year
|
45.5 score on a scale
Standard Deviation 5.3
|
|
Oxford Hip Score
7 Year
|
44.8 score on a scale
Standard Deviation 6.7
|
|
Oxford Hip Score
10 Year
|
45.5 score on a scale
Standard Deviation 4.5
|
SECONDARY outcome
Timeframe: pre-op, 6 Months, 1 Year, 2 Year, 3 Year, 5 Year, 7 Year, 10 YearPopulation: Due to lost to follow-up, withdrawals, visit not being performed the number of participants analyzed in each time-point is different.
The case administered University of California at Los Angeles (UCLA) score allows assessment of the case's activity level at each time point with scores from 1 (Wholly inactive: dependent on others; cannot leave residence) to 10 (Regularly participates in impact sports). Higher scores mean a better outcome
Outcome measures
| Measure |
Patients Who Received the Allofit IT With HXPE
n=194 Participants
Subjects in need of a primary total hip arthroplasty, who met the inclusion/exclusion criteria and who received the Allofit IT Shell in combination with the Longevity HXPE Liners
|
|---|---|
|
UCLA Activity Score
Pre-Op
|
4.3 score on a scale
Standard Deviation 1.7
|
|
UCLA Activity Score
6 months
|
5.8 score on a scale
Standard Deviation 1.8
|
|
UCLA Activity Score
1 Year
|
6.0 score on a scale
Standard Deviation 1.7
|
|
UCLA Activity Score
2 Year
|
6.7 score on a scale
Standard Deviation 1.3
|
|
UCLA Activity Score
3 Year
|
6.7 score on a scale
Standard Deviation 1.5
|
|
UCLA Activity Score
5 Year
|
6.7 score on a scale
Standard Deviation 1.7
|
|
UCLA Activity Score
7 Year
|
6.6 score on a scale
Standard Deviation 1.9
|
|
UCLA Activity Score
10 Year
|
6.5 score on a scale
Standard Deviation 1.8
|
SECONDARY outcome
Timeframe: pre-op, 6 Months, 1 Year, 2 Year, 3 Year, 5 Year, 7 Year, 10 YearPopulation: Due to lost to follow-up, withdrawals, visit not being performed the number of participants analyzed in each time-point is different.
X-rays evaluated for radiolucencies, osteolysis, hypertrophy, subsidence,heterotopic ossification, etc
Outcome measures
| Measure |
Patients Who Received the Allofit IT With HXPE
n=196 Participants
Subjects in need of a primary total hip arthroplasty, who met the inclusion/exclusion criteria and who received the Allofit IT Shell in combination with the Longevity HXPE Liners
|
|---|---|
|
Radiographic Evaluations - Acetabular Site
3 Year · Radiolucency
|
1 Participants
|
|
Radiographic Evaluations - Acetabular Site
3 Year · None
|
131 Participants
|
|
Radiographic Evaluations - Acetabular Site
3 Year · Screw breakage
|
0 Participants
|
|
Radiographic Evaluations - Acetabular Site
5 Year · Bone Condensation
|
1 Participants
|
|
Radiographic Evaluations - Acetabular Site
5 Year · Cup migration
|
0 Participants
|
|
Radiographic Evaluations - Acetabular Site
5 Year · Osteolysis
|
1 Participants
|
|
Radiographic Evaluations - Acetabular Site
5 Year · Radiolucency
|
0 Participants
|
|
Radiographic Evaluations - Acetabular Site
5 Year · None
|
108 Participants
|
|
Radiographic Evaluations - Acetabular Site
5 Year · Screw breakage
|
0 Participants
|
|
Radiographic Evaluations - Acetabular Site
7 Year · Bone Condensation
|
0 Participants
|
|
Radiographic Evaluations - Acetabular Site
7 Year · Cup migration
|
0 Participants
|
|
Radiographic Evaluations - Acetabular Site
7 Year · Osteolysis
|
0 Participants
|
|
Radiographic Evaluations - Acetabular Site
7 Year · Radiolucency
|
0 Participants
|
|
Radiographic Evaluations - Acetabular Site
7 Year · None
|
96 Participants
|
|
Radiographic Evaluations - Acetabular Site
7 Year · Screw breakage
|
0 Participants
|
|
Radiographic Evaluations - Acetabular Site
10 Year · Bone Condensation
|
0 Participants
|
|
Radiographic Evaluations - Acetabular Site
10 Year · Cup migration
|
0 Participants
|
|
Radiographic Evaluations - Acetabular Site
10 Year · Osteolysis
|
0 Participants
|
|
Radiographic Evaluations - Acetabular Site
10 Year · Radiolucency
|
0 Participants
|
|
Radiographic Evaluations - Acetabular Site
10 Year · None
|
94 Participants
|
|
Radiographic Evaluations - Acetabular Site
10 Year · Screw breakage
|
0 Participants
|
|
Radiographic Evaluations - Acetabular Site
1 Year · Radiolucency
|
1 Participants
|
|
Radiographic Evaluations - Acetabular Site
1 Year · None
|
171 Participants
|
|
Radiographic Evaluations - Acetabular Site
1 Year · Screw breakage
|
0 Participants
|
|
Radiographic Evaluations - Acetabular Site
2 Year · Bone Condensation
|
1 Participants
|
|
Radiographic Evaluations - Acetabular Site
2 Year · Cup migration
|
0 Participants
|
|
Radiographic Evaluations - Acetabular Site
2 Year · Osteolysis
|
0 Participants
|
|
Radiographic Evaluations - Acetabular Site
2 Year · Radiolucency
|
0 Participants
|
|
Radiographic Evaluations - Acetabular Site
2 Year · None
|
123 Participants
|
|
Radiographic Evaluations - Acetabular Site
2 Year · Screw breakage
|
0 Participants
|
|
Radiographic Evaluations - Acetabular Site
3 Year · Bone Condensation
|
1 Participants
|
|
Radiographic Evaluations - Acetabular Site
3 Year · Cup migration
|
0 Participants
|
|
Radiographic Evaluations - Acetabular Site
3 Year · Osteolysis
|
0 Participants
|
|
Radiographic Evaluations - Acetabular Site
6 Months · None
|
175 Participants
|
|
Radiographic Evaluations - Acetabular Site
6 Months · Screw breakage
|
0 Participants
|
|
Radiographic Evaluations - Acetabular Site
1 Year · Bone Condensation
|
1 Participants
|
|
Radiographic Evaluations - Acetabular Site
1 Year · Cup migration
|
1 Participants
|
|
Radiographic Evaluations - Acetabular Site
1 Year · Osteolysis
|
0 Participants
|
|
Radiographic Evaluations - Acetabular Site
Immediat PostOp · Bone Condensation
|
0 Participants
|
|
Radiographic Evaluations - Acetabular Site
Immediat PostOp · Cup migration
|
1 Participants
|
|
Radiographic Evaluations - Acetabular Site
Immediat PostOp · Osteolysis
|
0 Participants
|
|
Radiographic Evaluations - Acetabular Site
Immediat PostOp · Radiolucency
|
6 Participants
|
|
Radiographic Evaluations - Acetabular Site
Immediat PostOp · None
|
188 Participants
|
|
Radiographic Evaluations - Acetabular Site
Immediat PostOp · Screw breakage
|
1 Participants
|
|
Radiographic Evaluations - Acetabular Site
6 Months · Bone Condensation
|
0 Participants
|
|
Radiographic Evaluations - Acetabular Site
6 Months · Cup migration
|
0 Participants
|
|
Radiographic Evaluations - Acetabular Site
6 Months · Osteolysis
|
0 Participants
|
|
Radiographic Evaluations - Acetabular Site
6 Months · Radiolucency
|
3 Participants
|
SECONDARY outcome
Timeframe: pre-op, 6 Months, 1 Year, 2 Year, 3 Year, 5 Year, 7 Year, 10 YearPopulation: Due to lost to follow-up, withdrawals, visit not being performed the number of participants analyzed in each time-point is different.
X-rays evaluated for radiolucencies, osteolysis, hypertrophy, subsidence,heterotopic ossification, etc
Outcome measures
| Measure |
Patients Who Received the Allofit IT With HXPE
n=196 Participants
Subjects in need of a primary total hip arthroplasty, who met the inclusion/exclusion criteria and who received the Allofit IT Shell in combination with the Longevity HXPE Liners
|
|---|---|
|
Radiographic Evaluations - Femoral Side
Immediat PostOp · Stem Shift
|
0 Participants
|
|
Radiographic Evaluations - Femoral Side
Immediat PostOp · Stem Subsidence Subsidence
|
6 Participants
|
|
Radiographic Evaluations - Femoral Side
Immediat PostOp · Calcar rounding
|
5 Participants
|
|
Radiographic Evaluations - Femoral Side
Immediat PostOp · Calcar resorption
|
3 Participants
|
|
Radiographic Evaluations - Femoral Side
Immediat PostOp · Abnormalities
|
0 Participants
|
|
Radiographic Evaluations - Femoral Side
Immediat PostOp · Heterotopic Ossification
|
0 Participants
|
|
Radiographic Evaluations - Femoral Side
Immediat PostOp · AP- View: Radiolucency
|
1 Participants
|
|
Radiographic Evaluations - Femoral Side
Immediat PostOp · AP- View: Osteolysis
|
0 Participants
|
|
Radiographic Evaluations - Femoral Side
Immediat PostOp · Lateral - View: Radiolucency
|
0 Participants
|
|
Radiographic Evaluations - Femoral Side
Immediat PostOp · Lateral - View: Osteolysis
|
1 Participants
|
|
Radiographic Evaluations - Femoral Side
Immediat PostOp · None
|
180 Participants
|
|
Radiographic Evaluations - Femoral Side
6 Months · Stem Shift
|
1 Participants
|
|
Radiographic Evaluations - Femoral Side
6 Months · Stem Subsidence Subsidence
|
6 Participants
|
|
Radiographic Evaluations - Femoral Side
6 Months · Calcar rounding
|
55 Participants
|
|
Radiographic Evaluations - Femoral Side
6 Months · Calcar resorption
|
5 Participants
|
|
Radiographic Evaluations - Femoral Side
6 Months · Abnormalities
|
1 Participants
|
|
Radiographic Evaluations - Femoral Side
6 Months · Heterotopic Ossification
|
3 Participants
|
|
Radiographic Evaluations - Femoral Side
6 Months · AP- View: Radiolucency
|
2 Participants
|
|
Radiographic Evaluations - Femoral Side
6 Months · AP- View: Osteolysis
|
2 Participants
|
|
Radiographic Evaluations - Femoral Side
6 Months · Lateral - View: Radiolucency
|
0 Participants
|
|
Radiographic Evaluations - Femoral Side
6 Months · Lateral - View: Osteolysis
|
1 Participants
|
|
Radiographic Evaluations - Femoral Side
6 Months · None
|
103 Participants
|
|
Radiographic Evaluations - Femoral Side
1 Year · Stem Shift
|
3 Participants
|
|
Radiographic Evaluations - Femoral Side
1 Year · Stem Subsidence Subsidence
|
4 Participants
|
|
Radiographic Evaluations - Femoral Side
1 Year · Calcar rounding
|
68 Participants
|
|
Radiographic Evaluations - Femoral Side
1 Year · Calcar resorption
|
5 Participants
|
|
Radiographic Evaluations - Femoral Side
1 Year · Abnormalities
|
0 Participants
|
|
Radiographic Evaluations - Femoral Side
1 Year · Heterotopic Ossification
|
2 Participants
|
|
Radiographic Evaluations - Femoral Side
1 Year · AP- View: Radiolucency
|
6 Participants
|
|
Radiographic Evaluations - Femoral Side
1 Year · AP- View: Osteolysis
|
1 Participants
|
|
Radiographic Evaluations - Femoral Side
1 Year · Lateral - View: Radiolucency
|
0 Participants
|
|
Radiographic Evaluations - Femoral Side
1 Year · Lateral - View: Osteolysis
|
2 Participants
|
|
Radiographic Evaluations - Femoral Side
1 Year · None
|
83 Participants
|
|
Radiographic Evaluations - Femoral Side
2 Year · Stem Shift
|
1 Participants
|
|
Radiographic Evaluations - Femoral Side
2 Year · Stem Subsidence Subsidence
|
0 Participants
|
|
Radiographic Evaluations - Femoral Side
2 Year · Calcar rounding
|
62 Participants
|
|
Radiographic Evaluations - Femoral Side
2 Year · Calcar resorption
|
2 Participants
|
|
Radiographic Evaluations - Femoral Side
2 Year · Abnormalities
|
0 Participants
|
|
Radiographic Evaluations - Femoral Side
2 Year · Heterotopic Ossification
|
1 Participants
|
|
Radiographic Evaluations - Femoral Side
2 Year · AP- View: Radiolucency
|
5 Participants
|
|
Radiographic Evaluations - Femoral Side
2 Year · AP- View: Osteolysis
|
0 Participants
|
|
Radiographic Evaluations - Femoral Side
2 Year · Lateral - View: Radiolucency
|
1 Participants
|
|
Radiographic Evaluations - Femoral Side
2 Year · Lateral - View: Osteolysis
|
0 Participants
|
|
Radiographic Evaluations - Femoral Side
2 Year · None
|
52 Participants
|
|
Radiographic Evaluations - Femoral Side
3 Year · Stem Shift
|
1 Participants
|
|
Radiographic Evaluations - Femoral Side
3 Year · Stem Subsidence Subsidence
|
0 Participants
|
|
Radiographic Evaluations - Femoral Side
3 Year · Calcar rounding
|
56 Participants
|
|
Radiographic Evaluations - Femoral Side
3 Year · Calcar resorption
|
1 Participants
|
|
Radiographic Evaluations - Femoral Side
3 Year · Abnormalities
|
0 Participants
|
|
Radiographic Evaluations - Femoral Side
3 Year · Heterotopic Ossification
|
4 Participants
|
|
Radiographic Evaluations - Femoral Side
3 Year · AP- View: Radiolucency
|
5 Participants
|
|
Radiographic Evaluations - Femoral Side
3 Year · AP- View: Osteolysis
|
1 Participants
|
|
Radiographic Evaluations - Femoral Side
3 Year · Lateral - View: Radiolucency
|
3 Participants
|
|
Radiographic Evaluations - Femoral Side
3 Year · Lateral - View: Osteolysis
|
1 Participants
|
|
Radiographic Evaluations - Femoral Side
3 Year · None
|
61 Participants
|
|
Radiographic Evaluations - Femoral Side
5 Year · Stem Shift
|
1 Participants
|
|
Radiographic Evaluations - Femoral Side
5 Year · Stem Subsidence Subsidence
|
0 Participants
|
|
Radiographic Evaluations - Femoral Side
5 Year · Calcar rounding
|
50 Participants
|
|
Radiographic Evaluations - Femoral Side
5 Year · Calcar resorption
|
3 Participants
|
|
Radiographic Evaluations - Femoral Side
5 Year · Abnormalities
|
0 Participants
|
|
Radiographic Evaluations - Femoral Side
5 Year · Heterotopic Ossification
|
4 Participants
|
|
Radiographic Evaluations - Femoral Side
5 Year · AP- View: Radiolucency
|
6 Participants
|
|
Radiographic Evaluations - Femoral Side
5 Year · AP- View: Osteolysis
|
1 Participants
|
|
Radiographic Evaluations - Femoral Side
5 Year · Lateral - View: Radiolucency
|
1 Participants
|
|
Radiographic Evaluations - Femoral Side
5 Year · Lateral - View: Osteolysis
|
1 Participants
|
|
Radiographic Evaluations - Femoral Side
5 Year · None
|
43 Participants
|
|
Radiographic Evaluations - Femoral Side
7 Year · Stem Shift
|
0 Participants
|
|
Radiographic Evaluations - Femoral Side
7 Year · Stem Subsidence Subsidence
|
0 Participants
|
|
Radiographic Evaluations - Femoral Side
7 Year · Calcar rounding
|
52 Participants
|
|
Radiographic Evaluations - Femoral Side
7 Year · Calcar resorption
|
1 Participants
|
|
Radiographic Evaluations - Femoral Side
7 Year · Abnormalities
|
1 Participants
|
|
Radiographic Evaluations - Femoral Side
7 Year · Heterotopic Ossification
|
5 Participants
|
|
Radiographic Evaluations - Femoral Side
7 Year · AP- View: Radiolucency
|
6 Participants
|
|
Radiographic Evaluations - Femoral Side
7 Year · AP- View: Osteolysis
|
1 Participants
|
|
Radiographic Evaluations - Femoral Side
7 Year · Lateral - View: Radiolucency
|
0 Participants
|
|
Radiographic Evaluations - Femoral Side
7 Year · Lateral - View: Osteolysis
|
0 Participants
|
|
Radiographic Evaluations - Femoral Side
7 Year · None
|
30 Participants
|
|
Radiographic Evaluations - Femoral Side
10 Year · Stem Shift
|
0 Participants
|
|
Radiographic Evaluations - Femoral Side
10 Year · Stem Subsidence Subsidence
|
0 Participants
|
|
Radiographic Evaluations - Femoral Side
10 Year · Calcar rounding
|
45 Participants
|
|
Radiographic Evaluations - Femoral Side
10 Year · Heterotopic Ossification
|
3 Participants
|
|
Radiographic Evaluations - Femoral Side
10 Year · AP- View: Radiolucency
|
5 Participants
|
|
Radiographic Evaluations - Femoral Side
10 Year · AP- View: Osteolysis
|
2 Participants
|
|
Radiographic Evaluations - Femoral Side
10 Year · Lateral - View: Radiolucency
|
1 Participants
|
|
Radiographic Evaluations - Femoral Side
10 Year · Lateral - View: Osteolysis
|
2 Participants
|
|
Radiographic Evaluations - Femoral Side
10 Year · None
|
34 Participants
|
|
Radiographic Evaluations - Femoral Side
10 Year · Calcar resorption
|
2 Participants
|
|
Radiographic Evaluations - Femoral Side
10 Year · Abnormalities
|
0 Participants
|
Adverse Events
Patients Who Received the Allofit IT With HXPE
Serious adverse events
| Measure |
Patients Who Received the Allofit IT With HXPE
n=197 participants at risk
Subjects in need of a primary total hip arthroplasty, who met the inclusion/exclusion criteria and who received the Allofit IT Shell in combination with the Longevity HXPE Liners
|
|---|---|
|
Cardiac disorders
General
|
4.1%
8/197 • Number of events 13 • 10 years post-surgery
Same definitions
|
|
Renal and urinary disorders
General
|
0.51%
1/197 • Number of events 1 • 10 years post-surgery
Same definitions
|
|
Infections and infestations
General
|
0.51%
1/197 • Number of events 1 • 10 years post-surgery
Same definitions
|
|
Musculoskeletal and connective tissue disorders
General
|
8.6%
17/197 • Number of events 18 • 10 years post-surgery
Same definitions
|
|
Nervous system disorders
General
|
0.51%
1/197 • Number of events 2 • 10 years post-surgery
Same definitions
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
General
|
3.6%
7/197 • Number of events 8 • 10 years post-surgery
Same definitions
|
|
Respiratory, thoracic and mediastinal disorders
General
|
1.0%
2/197 • Number of events 3 • 10 years post-surgery
Same definitions
|
|
General disorders
General
|
5.1%
10/197 • Number of events 13 • 10 years post-surgery
Same definitions
|
|
Product Issues
Hip Related
|
1.5%
3/197 • Number of events 5 • 10 years post-surgery
Same definitions
|
Other adverse events
| Measure |
Patients Who Received the Allofit IT With HXPE
n=197 participants at risk
Subjects in need of a primary total hip arthroplasty, who met the inclusion/exclusion criteria and who received the Allofit IT Shell in combination with the Longevity HXPE Liners
|
|---|---|
|
Gastrointestinal disorders
General Complications - Adverse Events
|
1.0%
2/197 • Number of events 4 • 10 years post-surgery
Same definitions
|
|
Musculoskeletal and connective tissue disorders
General Complications - Adverse Events
|
4.1%
8/197 • Number of events 17 • 10 years post-surgery
Same definitions
|
|
General disorders
General Complications - Adverse Events
|
1.5%
3/197 • Number of events 13 • 10 years post-surgery
Same definitions
|
|
Product Issues
Hip Related Complications - Adverse Events
|
2.0%
4/197 • Number of events 8 • 10 years post-surgery
Same definitions
|
|
Vascular disorders
Hip Related Complications - Adverse Events
|
1.5%
3/197 • Number of events 3 • 10 years post-surgery
Same definitions
|
|
General disorders
Hip Related Complications - Adverse Events
|
1.5%
3/197 • Number of events 3 • 10 years post-surgery
Same definitions
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place